prnewswire.com
Positivewww.prnewswire.com ·
hugel reports record q1 earnings driving strong global growth in aesthetics 302765087
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedHugel Inc., a South Korean medical aesthetics company, reported record Q1 earnings driven by strong overseas demand for botulinum toxin and dermal fillers, particularly in the U.S., China, Europe, and Brazil. The commercial mechanism is a demand_spike for aesthetic injectables, expanding Hugel's revenue and margins. The impact is company-specific (Hugel) and its supply chain, not a broad sector shift. No scarcity or price pass-through is indicated.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Hugel Inc. reported Q1 2023 net sales of KRW116.6 billion, up 29.9% YoY.
- Operating profit reached KRW47.6 billion, up 22.3% YoY.
- Overseas sales of toxins and dermal fillers surged 46% to KRW21 billion.
- Botulinum toxin sales rose 60.6% to KRW65.4 billion.
- Dermal fillers and skin boosters totaled KRW32.1 billion.